Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

That Was Easy: PDUFA Bill Clears House Subcommittee Without Debate

This article was originally published in The Pink Sheet Daily

Executive Summary

Opening statements in the House Energy and Commerce’s Health Subcommittee’s markup took longer than the legislative activity, which consisted of a technical amendment and two colloquys. Next stop on the user fee express: Upton-town on Thursday.

You may also be interested in...



PDUFA Stars Aligning As House Draft Gives FDA Direct Authority Over Importers

Latest version of potential House user fee bill eliminates revisions to FDA’s mission statement and includes provisions for approving breakthrough technologies and destroying unsafe drug imports at the border.

User Fee Legislation Revs Through Senate Mark-up, But House Bill Goes Back Into The Shop

Senate health committee defers action on several potentially contentious issues, with members hoping to resolve differences over FDA’s authorities on imports, shortages, foreign data and track-and-trace before the bill goes to the floor, possibly in May. Meanwhile, the House postpones its mark-up in an effort to craft a more bipartisan bill, and now will try to push the user fee package to the floor during an upcoming four-day marathon session.

Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain

Rep. Phil Gingrey, lead sponsor of the Generating Antibiotic Incentives Now Act, says industry still has questions about the proposed approval pathway for antibiotics treating life-threatening diseases, further clouding its prospects.

Topics

Latest News
UsernamePublicRestriction

Register

PS074217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel